# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-02-02
**æ›´æ–°æ—¶é—´**: 2026-02-03 04:14
**æ–°é—»æ•°é‡**: 106

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºé‡ç£…è¯ç‰©çš„ç ”å‘è¿›å±•ä¸ç›‘ç®¡åŠ¨æ€ã€‚è¯ºå’Œè¯ºå¾·ï¼ˆNovo Nordiskï¼‰çš„ä¸‹ä¸€ä»£ä»£è°¢è¯ç‰©CagriSemaåœ¨IIæœŸè¯•éªŒä¸­æ˜¾ç¤ºå‡ºä¼˜äºå¸ç¾æ ¼é²è‚½ï¼ˆsemaglutideï¼‰çš„é™ç³–å‡é‡æ•ˆæœï¼Œå·©å›ºäº†å…¶åœ¨GLP-1é¢†åŸŸçš„é¢†å…ˆåœ°ä½ï¼›åŒæ—¶ï¼Œå…¶å¸ç¾æ ¼é²è‚½åœ¨æ¬§æ´²è·å¾—CHMPå¯¹MASHé€‚åº”ç—‡çš„ç§¯ææ„è§ã€‚å¦ä¸€æ–¹é¢ï¼Œå®‰è¿›ï¼ˆAmgenï¼‰å› æ•°æ®å®Œæ•´æ€§é—®é¢˜é¢ä¸´å·²è·æ‰¹è¯ç‰©Tavneosçš„é‡æ–°å®¡æŸ¥ï¼Œå¹¶ç»ˆæ­¢äº†ä¸åå’Œéº’éºŸï¼ˆKyowa Kirinï¼‰åœ¨å…ç–«å­¦è¯ç‰©ä¸Šçš„åˆä½œï¼Œåæ˜ äº†ç ”å‘ä¸ç›‘ç®¡å±‚é¢çš„æŒ‘æˆ˜ã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**9. New CagriSema data show improvement over semaglutide** â­â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - è¯ºå’Œè¯ºå¾·ä¸‹ä¸€ä»£ä»£è°¢è¯ç‰©CagriSemaåœ¨IIæœŸè¯•éªŒä¸­é™ç³–å‡é‡æ•ˆæœä¼˜äºé‡ç£…è¯ç‰©å¸ç¾æ ¼é²è‚½ï¼Œå¯èƒ½é‡å¡‘ç³–å°¿ç—…/è‚¥èƒ–ç—‡æ²»ç–—æ ¼å±€ã€‚

**3. CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - å¸ç¾æ ¼é²è‚½è·CHMPå¯¹MASHé€‚åº”ç—‡çš„ç§¯ææ„è§ï¼Œå¸‚åœºæ½œåŠ›å·¨å¤§ï¼›åŒæ—¶å®‰è¿›å·²è·æ‰¹è¯ç‰©å› æ•°æ®é—®é¢˜é¢ä¸´é‡å®¡ï¼Œå‡¸æ˜¾ç›‘ç®¡é£é™©ã€‚

**1. Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 wins** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - å®‰è¿›åœ¨IIIæœŸæˆåŠŸèƒŒæ™¯ä¸‹çªç„¶ç»ˆæ­¢ä¸åå’Œéº’éºŸçš„é‡è¦å…ç–«å­¦è¯ç‰©åˆä½œï¼Œå¼•å‘å¯¹ç®¡çº¿æˆ˜ç•¥åŠåˆä½œç¨³å®šæ€§çš„å…³æ³¨ã€‚

**23. AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - é˜¿æ–¯åˆ©åº·å®£å¸ƒè‡³2030å¹´å‘ä¸­å›½æŠ•èµ„150äº¿ç¾å…ƒï¼Œé‡ç‚¹åŠ å¼ºç»†èƒç–—æ³•å’Œæ”¾å°„æ€§å¶è”è¯ç‰©èƒ½åŠ›ï¼Œæ˜¯è¿‘å¹´æ¥å¯¹åæœ€å¤§æŠ•èµ„æ‰¿è¯ºä¹‹ä¸€ã€‚

**18. Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in PA** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - ç¤¼æ¥å®£å¸ƒæŠ•èµ„35äº¿ç¾å…ƒåœ¨ç¾å›½å»ºè®¾æ–°çš„æ³¨å°„å‰‚å’Œè®¾å¤‡å·¥å‚ï¼Œå®Œæˆå…¶â€œç¾å›½åˆ¶é€ â€æŠ•èµ„è®¡åˆ’ï¼Œä»¥åº”å¯¹GLP-1è¯ç‰©ç­‰å·¨å¤§äº§èƒ½éœ€æ±‚ã€‚

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): è¯ºå’Œè¯ºå¾·CagriSemaæ•°æ®ä¼˜å¼‚ï¼Œé˜¿æ–¯åˆ©åº·ä¸CSPCè¾¾æˆæ½œåœ¨è¶…180äº¿ç¾å…ƒçš„ä¸‹ä¸€ä»£å‡è‚¥è¯å¹¿æ³›è”ç›Ÿï¼Œè¡Œä¸šåœ¨ä»£è°¢ç–¾ç—…é¢†åŸŸç«äº‰ç™½çƒ­åŒ–ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): å…³é”®è¿›å±•åŒ…æ‹¬CagriSemaåœ¨IIæœŸç³–å°¿ç—…è¯•éªŒä¸­ä¼˜äºå¸ç¾æ ¼é²è‚½çš„æ•°æ®ï¼Œä»¥åŠåå’Œéº’éºŸæŠ«éœ²å…¶æ¹¿ç–¹è¯ç‰©IIIæœŸè¯•éªŒä¸­çš„å‰¯ä½œç”¨ä¿¡æ¯ã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

éœ€æŒç»­å…³æ³¨è¯ºå’Œè¯ºå¾·CagriSemaåç»­ä¸´åºŠå¼€å‘è®¡åˆ’åŠå…¶å¯¹ç¤¼æ¥Zepboundçš„ç«äº‰å½±å“ï¼›å®‰è¿›Tavneosæ•°æ®å®Œæ•´æ€§é‡å®¡çš„è¿›å±•ä¸æ½œåœ¨ç›‘ç®¡åæœï¼›ä»¥åŠFDA PreCheckåˆ¶é€ åŠ é€Ÿè®¡åˆ’çš„ç”³è¯·ä¸å®æ–½åˆæœŸåé¦ˆã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç»¼åˆ (ç»¼åˆ) | 44 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 wins

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 16:04
- **é‡è¦æ€§**: â­â­â­â­â­

> Amgen abruptly pulled out of a collaboration for a leading drug in its immunology pipeline on Friday, sending the asset back to its partner ahead of an FDA submission later this year. Amgen terminated its ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/amgen-ends-partnership-with-kyowa-kirin-on-immunology-drug-despite-phase-3-wins/)

---

### ğŸ‡ºğŸ‡¸ First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 20:42
- **é‡è¦æ€§**: â­â­â­â­

> The first 10 drugs that underwent government price negotiations in 2023 were projected to save the government billions of dollars. Now, one month since the new pricing took effect, the extent to which those savings ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/first-10-medicare-negotiated-drug-prices-have-taken-effect-are-seniors-really-saving-money/)

---

### ğŸ‡ºğŸ‡¸ Amgen gives up on its once-prized eczema drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-30 16:57
- **é‡è¦æ€§**: â­â­â­

> The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/amgen-return-rocatinlimab-kyowa-kirin-atopic-dermatitis-eczma-ox40/810964/)

---

### ğŸ‡ºğŸ‡¸ New CagriSema data show improvement over semaglutide

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 19:16
- **é‡è¦æ€§**: â­â­â­

> Novo Nordiskâ€™s next-gen metabolic drug CagriSema performed better than the blockbuster semaglutide at reducing blood sugar and weight in patients with type 2 diabetes. That was the topline result from the latest Phase 3 readout ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/new-cagrisema-data-show-improvement-over-semaglutide/)

---

### ğŸ‡ºğŸ‡¸ Kyowa Kirin reveals side effect in trial; GSK was lone bidder for RAPT

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 15:22
- **é‡è¦æ€§**: â­â­â­

> Plus, news on AstraZeneca, Johnson &amp; Johnson, Averin Capital and Chugai: ğŸ§ª Kyowa Kirin discloses side effect for recently regained drug: A patient participating in a Phase 3 trial to treat eczema developed a case ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/kyowa-kirin-reveals-side-effect-in-trial-gsk-was-lone-bidder-for-rapt/)

---

### ğŸ‡ºğŸ‡¸ Novo combination obesity shot meets goal in diabetes trial

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 19:00
- **é‡è¦æ€§**: â­â­

> CagriSema&rsquo;s blood sugar and weight reductions exceeded the company&rsquo;s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/novo-cagrisema-diabetes-reimagine-study-results/811115/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca leans into obesity, striking wide-ranging alliance with Chinaâ€™s CSPC

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-30 12:36
- **é‡è¦æ€§**: â­â­

> The deal, which involves up to eight &ldquo;next-generation&rdquo; weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/astrazeneca-obesity-deal-china-cspc-ai/810942/)

---

### ğŸ‡ºğŸ‡¸ Politicization runs deeper than ever at FDA, risking long-term impacts

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-30 12:00
- **é‡è¦æ€§**: â­â­

> A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration&rsquo;s political agenda, according to an economist and public policy expert.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/fda-politicization-deeper-than-ever-risking-long-term-impacts/810909/)

---

### ğŸ‡ºğŸ‡¸ FDA rejects Aquestive's allergy drug over packaging issues

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 15:17
- **é‡è¦æ€§**: â­â­

> The FDA has delivered a complete response letter to Aquestive Therapeutics for its allergy medication due to issues over the drugâ€™s packaging. The agency declined to approve Aquestiveâ€™s allergy patch called Anaphylm in patients weighing ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-rejects-aquestives-allergy-drug-over-packaging-issues/)

---

### ğŸ‡ºğŸ‡¸ FDA opens submissions for PreCheck program to speed up US factory builds

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 14:46
- **é‡è¦æ€§**: â­â­

> The FDA has started accepting pitches for drugmakers to participate in the agencyâ€™s PreCheck program, a new initiative aimed to speed up the construction of US manufacturing sites. The agency

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-opens-submissions-for-precheck-program-to-speed-up-us-factory-builds/)

---

### ğŸ‡ºğŸ‡¸ Pharmingâ€™s immunodeficiency drug gets CRL for use in younger patients

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 11:52
- **é‡è¦æ€§**: â­â­

> The FDA has issued a complete response letter to Pharming, rejecting its attempt to expand the approval of its drug for a rare form of immunodeficiency into younger patients. Joenja was

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/pharmings-immunodeficiency-drug-gets-crl-for-use-in-younger-patients/)

---

### ğŸ‡ºğŸ‡¸ FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 19:14
- **é‡è¦æ€§**: â­â­

> An FDA rejection letter for Corcept Therapeuticsâ€™ potential hormonal disorder drug says the agency told the company it had serious concerns before the application was submitted. The complete response letter, released ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-says-it-explained-issues-early-on-for-corcepts-rejected-cushings-syndrome-drug/)

---

### ğŸ‡ºğŸ‡¸ CHMP opposes Lillyâ€™s Mounjaro in heart failure, backs Novoâ€™s Kayshild

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 17:18
- **é‡è¦æ€§**: â­â­

> EU regulators have refused to greenlight Eli Lillyâ€™s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordiskâ€™s semaglutide in liver disease. Lilly failed to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/chmp-opposes-lillys-mounjaro-in-heart-failure-backs-novos-kayshild/)

---

### ğŸ‡ºğŸ‡¸ Ultragenyx resubmits gene therapy for rare neuro disease to FDA

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 16:50
- **é‡è¦æ€§**: â­â­

> Ultragenyx has resubmitted its approval request for a rare disease gene therapy after the FDA rejected it last summer. UX111 is an AAV gene therapy designed to treat Sanfilippo syndrome type A. The company is ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/ultragenyx-resubmits-gene-therapy-for-rare-neuro-disease-to-fda/)

---

### ğŸ‡ºğŸ‡¸ Lilly unveils $3.5B factory that will make retatrutide and other obesity drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 16:00
- **é‡è¦æ€§**: â­â­

> Eli Lilly has budgeted $3.5 billion for a new weight loss injectable and device factory in Lehigh Valley, PA, which will manufacture its next-gen obesity drug retatrutide. The factory will also produce other weight loss ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/lilly-unveils-3-5b-factory-that-will-make-retatrutide-and-other-obesity-drugs/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 10:36
- **é‡è¦æ€§**: â­â­

> AstraZeneca is already delivering on its $15 billion commitment to China with a $1.2 billion upfront pact with CSPC Pharmaceutical, spanning eight drug programs and multiple platform technologies. On Thursday, the UK ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/astrazeneca-pays-1-2b-for-cspcs-long-acting-obesity-drugs/)

---

### ğŸ‡ºğŸ‡¸ Sanofiâ€™s venglustat succeeds in Phase 3 Gaucher trial but fails separate study in Fabry disease

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 12:12
- **é‡è¦æ€§**: â­

> Sanofiâ€™s investigational drug, with a track record of mixed results in the clinic, has passed a Phase 3 trial in Gaucher disease, but flunked a separate late-stage study in Fabry disease.

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/sanofis-venglustat-succeeds-in-phase-3-gaucher-trial-but-fails-separate-study-in-fabry-disease/)

---

### ğŸ‡ºğŸ‡¸ Bitterroot reverts to preclinical biotech in CD47 as CEO leaves

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 17:30
- **é‡è¦æ€§**: â­

> Bitterroot Bio, a biotech from leading minds in the CD47 field, appears to have returned to the discovery stage after attempting to expand the potential of the "don't eat me" signal from the cancer field ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/bitterroot-reverts-to-preclinical-biotech-in-cd47-as-ceo-leaves/)

---

### ğŸ‡ºğŸ‡¸ Quince's steroid therapy for rare disease fails, shares tank

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 16:17
- **é‡è¦æ€§**: â­

> Quince Therapeutics' once-monthly steroid-based treatment failed a Phase 3 trial for a rare genetic condition called ataxia-telangiectasia, prompting the Bay Area company to say it would stop development of the experimental ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/quinces-steroid-therapy-for-rare-disease-fails-shares-tank/)

---

### ğŸ‡ºğŸ‡¸ Moderna licenses Phase 3 asset to Recordati; ProMIS' private placement

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 16:05
- **é‡è¦æ€§**: â­

> Plus, news about Lexicon Pharmaceuticals, Vaxcyte, ALX Oncology, BioMarin and 2048 Ventures: ğŸ¤ Moderna signs rare disease drug deal with Recordati: The Italian drugmaker will pay Moderna $50 million upfront and ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/moderna-licenses-phase-3-asset-to-recordati-promis-private-placement/)

---

### ğŸ‡ºğŸ‡¸ Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 17:12

> The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/sanofi-venglustat-gaucher-fabry-study-results/811113/)

---

### ğŸ‡ºğŸ‡¸ GSK walks away from pioneering Wave RNA editing drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 13:31

> Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/wave-gsk-reacquire-rna-editing-drug-aatd/811067/)

---

### ğŸ‡ºğŸ‡¸ Building a robust in-process testing plan for cell therapy manufacturing success

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 10:00

> The roadmap to reliable inâ€‘process testing for cell therapy success.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/spons/building-a-robust-in-process-testing-plan-for-cell-therapy-manufacturing-su/810800/)

---

### ğŸ‡ºğŸ‡¸ The biopharma industry outlook on 2026: Optimism and tension

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 19:31

> A spike in M&amp;A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/biotech-pharma-trends-outlook-2026/810833/)

---

### ğŸ‡ºğŸ‡¸ Sanofi expects vaccine sales growth to dip amid â€˜challenging environmentâ€™

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 16:56

> On a conference call, executives cited &ldquo;confusion&rdquo; and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated slower growth in 2026. &nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/sanofi-vaccine-sales-fourth-quarter-2025-earnings/810829/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca strengthens China ties with planned $15B investment

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 15:46

> AstraZeneca&rsquo;s&nbsp;investment will &ldquo;span the value chain&rdquo; of drug research and development and comes amid a prolonged surge in dealmaking activity involving large pharmaceutical companies and their counterparts in China.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/astrazeneca-china-biotech-invest-drug-manufacturing/810847/)

---

### ğŸ‡ºğŸ‡¸ Carbon Health files for bankruptcy, seeking to sell or restructure

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 21:22

> Carbon Health has filed for bankruptcy protection and is seeking to restructure or sell itself, the urgent and primary care startup said Monday. The company voluntarily filed for Chapter 11 in the US Bankruptcy Court ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/carbon-health-files-for-bankruptcy-seeking-to-sell-or-restructure/)

---

### ğŸ‡ºğŸ‡¸ GSK returns rights to Wave's RNA editing program for AATD

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 16:06

> GSK no longer plans to collaborate on a closely-watched RNA editing program from Wave Life Sciences, whose fate could influence the prospects of the emerging field. Wave announced Monday that GSK ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/gsk-returns-rights-to-waves-rna-editing-program-for-aatd/)

---

### ğŸ‡ºğŸ‡¸ Spring Health acquires Alma, expanding insurance reach in virtual mental health

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 15:43

> Spring Health is the latest virtual mental health company to lean into insurance as it acquires competitor Alma. The deal, announced Thursday, would give Spring, which has traditionally focused on providing mental health services as ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/spring-health-acquires-alma-expanding-insurance-reach-in-virtual-mental-health/)

---

### ğŸ‡ºğŸ‡¸ SanegeneBio licenses RNAi candidate to Genentech for $200M upfront

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 14:35

> Genentech will pick up an RNAi candidate from SanegeneBio, a China and US biotech fresh off a $110 million Series B. The Roche unit will pay $200 million upfront for the global ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/sanegenebio-licenses-rnai-candidate-to-genentech-for-200m-upfront/)

---

### ğŸ‡ºğŸ‡¸ European law changes mean drugmakers may have to grapple with generic competition sooner

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 06:00

> European regulators will soon sign in a new raft of laws that could make drugmakers jump through more hoops to delay generic and biosimilar competition. And companies developing rare disease and orphan drugs are likely ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/imminent-european-law-changes-mean-drugmakers-may-have-to-grapple-with-generic-competition-sooner/)

---

### ğŸ‡ºğŸ‡¸ Big Pharma earnings kick off; Third-round IRA drugs selected; Hengruiâ€™s trailblazing moment; and more

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-31 11:00

> Welcome back to Endpoints Weekly! Fourth-quarter earnings season is in full swing, and our team covered reports this week from Teva, Roche, Sanofi, Takeda and Regeneron. CMS also unveiled the next 15 drugs subject to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/big-pharma-earnings-kick-off-third-round-ira-drugs-selected-hengruis-trailblazing-moment-and-more/)

---

### ğŸ‡ºğŸ‡¸ Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 12:00

> â†’ William Go has replaced Zachariah McIver as CMO of Janux Therapeutics, a San Diego-based biotech that is partnering with Bristol Myers Squibb on a T cell engager ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/janux-hires-cmo-after-t-cell-engager-deal-with-bristol-myers-a-batch-of-appointments-at-lexeo/)

---

### ğŸ‡ºğŸ‡¸ Reed Jobs' cancer biotech investment firm Yosemite eyes $350M fund

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 10:45

> Yosemite, the cancer research investment firm led by Reed Jobs, is looking to raise a fund worth up to $350 million, according to a Thursday SEC filing. The California-based investment firm ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/reed-jobs-cancer-biotech-investment-firm-yosemite-eyes-350m-fund/)

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ HER2+ Metastatic Gastroesophageal Adenocarcinoma: Why First-Line Innovation Canâ€™t Wait

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 12:08
- **é‡è¦æ€§**: â­â­â­â­

> Outcomes for HER2+ metastatic gastroesophageal adenocarcinoma remain poor, underscoring the need for more durable first-line options.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/sponsored/her2-metastatic-gastroesophageal-adenocarcinoma-why-first-line-innovation-cant-wait)

---

### ğŸ‡ºğŸ‡¸ CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 11:35
- **é‡è¦æ€§**: â­â­â­â­

> Sanofi, Novo Nordisk, UCB and others received positive opinions from Europe's Committee for Medicinal Products for Human Use, while Amgen's approved Tavneos is up for a re-review due to data integrity concerns.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/europes-chmp-thumbs-novos-semaglutide-mash-sanofis-rezurock-and-more-while-amgens-tavneos)

---

### ğŸ‡ºğŸ‡¸ CDMO Vetter maps out expansion in Germany with â‚¬480M for new plant

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 17:26
- **é‡è¦æ€§**: â­â­â­

> The German CDMO devoted 480 million euros ($574.3 million) to the first construction phase for a new plant in Saarlouis, Germany, which is expected to be operational by 2031.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/german-cdmo-vetter-takes-global-expansion-spree-its-home-country-eu480m-investment)

---

### ğŸ‡ºğŸ‡¸ With FDA rejections, Aquestive's shares go up, while Pharming's go down

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 11:15
- **é‡è¦æ€§**: â­â­

> The FDA issued complete response letters to Aquestive Therapeutics and Pharming in recent days, resulting in vastly different reactions from the market.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-rejections-aquestives-shares-go-while-pharmings-go-down)

---

### ğŸ‡ºğŸ‡¸ FDA emphasizes drug ingredients, production pledges as it debuts PreCheck manufacturing program

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 10:02
- **é‡è¦æ€§**: â­â­

> Amid an outpouring of industry investments in U.S. drug production, the FDA has launched a new program designed to reduce the complexities involved in setting up domestic manufacturing plants.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-emphasizes-drug-ingredients-production-pledges-it-debuts-precheck-manufacturing-program)

---

### ğŸ‡ºğŸ‡¸ A sales turnaround for Regeneron's Eylea franchise will have to wait at least another quarter

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 11:15
- **é‡è¦æ€§**: â­â­

> For the last several quarters, declining sales of Regeneron's eye disease treatment Eylea have exceeded increasing sales of the drug's new version, Eylea HD, leading to a steady decline in overall U.S. sales for the Eylea franchise. The company said Friday the trend will continue in the first quarter of this year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/turnaround-regenerons-eylea-will-have-wait-least-another-quarter)

---

### ğŸ‡ºğŸ‡¸ Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in PA

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 09:19
- **é‡è¦æ€§**: â­â­

> On Friday, Eli Lilly unveiled designs on a new, $3.5 billion manufacturing facility in Pennsylvaniaâ€™s Lehigh Valley, rounding out the quartet of plants it promised during its â€œLilly in Americaâ€ investment announcement last year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/lilly-rounds-out-quartet-new-us-plants-35b-injectables-and-device-facility-pa)

---

### ğŸ‡ºğŸ‡¸ ARS Pharma TV ad for epinephrine nasal spray Neffy needled by FDA in untitled letter

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 11:46
- **é‡è¦æ€§**: â­â­

> A few months after sending an untitled letter to ARS Pharmaceuticals, taking issue with certain aspects of a TV commercial about its epinephrine nasal spray, the FDA is reiterating its concerns about Neffyâ€™s advertising language.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/ars-pharma-tv-ad-epinephrine-nasal-spray-neffy-needled-fda-untitled-letter)

---

### ğŸ‡ºğŸ‡¸ Sanofi's vaccine ambitions unfazed by 'politics or sentiment in the now,' CEO Paul Hudson says

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 11:22
- **é‡è¦æ€§**: â­â­

> Amid mounting concerns about the state of vaccine policy in the U.S., Sanofi is keeping a cool head while acknowledging that sales of its immunizations are slated to dip slightly this year. The comments come as Sanofi reported Thursday that its total vaccine sales fell 2.5% in the fourth quarter and 1.2% for the entire year, reaching 7.9 billion euros (roughly $9.5 billion) for all of 2025.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/sanofi-stands-firm-against-us-policy-tumult-it-predicts-vaccine-sales-dip-26)

---

### ğŸ‡ºğŸ‡¸ 'Relax your tight end': Novartis Super Bowl ad drafts NFL stars for cheeky prostate cancer testing push

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 16:56
- **é‡è¦æ€§**: â­â­

> A year after debuting its first Super Bowl ad, Novartis is returning to advertisingâ€™s biggest stage on another awareness-raising mission, this time focusing on boosting prostate cancer screening.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/novartis-super-bowl-ad-drafts-nfl-stars-cheeky-prostate-cancer-testing-push)

---

### ğŸ‡ºğŸ‡¸ Tenpoint scores FDA nod for vision-correction eye drop Yuvezzi, plans Q2 launch with $235M in tow

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 23:53
- **é‡è¦æ€§**: â­â­

> Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA approval for Yuvezzi, a treatment for presbyopia, a common, age-related condition that makes it difficult to focus on nearby objects. The company also said that it has raised $235 million to fund the launch of the product.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/tenpoint-scores-fda-nod-vision-correction-eye-drop-yuvezzi)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 05:51
- **é‡è¦æ€§**: â­â­

> AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to enhance its capabilities in areas including cell therapies and radioconjugates.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/astrazeneca-vows-15b-china-investment-boost-cell-therapy-and-radioconjugate-capabilities)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about obesity drug sales, Indiaâ€™s biopharma research push, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 14:30
- **é‡è¦æ€§**: â­â­

> The long-held expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/02/obesity-lilly-novo-sanofi-india-pfizer-fda/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Lilly, Repertoire strike $2 billion autoimmune alliance

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 16:03
- **é‡è¦æ€§**: â­â­

> And other biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/biotech-news-lilly-repertoire-strike-autoimmune-alliance/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about AstraZeneca investing in China, an abandoned overdose antidote, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 14:23
- **é‡è¦æ€§**: â­â­

> AstraZeneca will invest $15 billion in China through 2030 to expand medicines manufacturing and research and development

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/29/astrazeneca-hologen-kickbacks-overdose-lilly-china/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Medicare drug prices, the EU-India trade deal, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 14:00
- **é‡è¦æ€§**: â­â­

> The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/28/medicare-pharma-india-europe-novo-lilly-advertising/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Fierce Pharma Asiaâ€”AZ's $15B China investment; Boehringer, Simcere's IBD deal; Daiichi's ADC growth push

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 15:08
- **é‡è¦æ€§**: â­

> AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the country. Boehringer Ingelheim secured a preclinical inflammatory bowel disease bispecific from Simcere. Daiichi Sankyo's U.S. chief talked about the successâ€”and challengesâ€”the company is seeing with Enhertu and Datroway. And more.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/az-15b-china-investment-boehringer-simcere-ibd-deal-daiichi-adc-growth-push)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a Roche obesity drug, a clash over 340B claims data, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 14:17
- **é‡è¦æ€§**: â­

> Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after the drug led to significant weight loss in a mid-stage trial

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/27/roche-obesity-menopause-china-lilly-340b-hospitals-bausch/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ AbbVie has â€˜Love in Mindâ€™ with new migraine educational campaign

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 12:11

> With Valentineâ€™s Day coming up, AbbVie has love on the brain. Ahead of the holiday, the Big Pharma has unveiled a new campaign focusing on how migraines can impact romantic relationships.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/abbvie-has-love-mind-new-migraine-educational-campaign)

---

### ğŸ‡ºğŸ‡¸ Thermo Fisher trims Massachusetts headcount with Franklin site closure

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 11:06

> Thermo Fisher is continuing its recent layoff spree with a fresh round of cuts tied to a site itâ€™s shuttering in Franklin, Massachusetts, which currently employs about 200 people.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/thermo-fisher-trims-massachusetts-headcount-franklin-site-closure)

---

### ğŸ‡ºğŸ‡¸ Why human expertise still matters in AI-driven med comms

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 16:32

> RTI Health Solutions experts explain how AI can help medical communications without replacing rigor, judgment or trust.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/sponsored/why-human-expertise-still-matters-ai-driven-med-comms)

---

### ğŸ‡ºğŸ‡¸ Trump administration officials are at loggerheads over future of COVID vaccines: Axios

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 06:55

> Some officials in the Trump administration are at odds with others who are helping shape vaccine policy over whether to remove COVID vaccines from the U.S. market, according to a report from Axios.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/trump-administration-officials-are-loggerheads-over-covid-vaccines-report)

---

### ğŸ‡ºğŸ‡¸ Quince Therapeutics on the brink as steroid-in-blood-cell fails in rare genetic disease

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 09:57

> Quince Therapeuticsâ€™ novel method of delivering steroids in a patientâ€™s own red blood cells turned out to be a bust in ataxia-telangiectasia, a rare inherited disorder, with the company now planning to â€œpreserve cash and explore available options.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/quince-therapeutics-teeters-edge-steroid-blood-cell-fails-rare-genetic-disease)

---

### ğŸ‡ºğŸ‡¸ Biopharma's rebound keeping pace so far

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 15:56

> This week on "The Top Line," we explore biopharma's rebound, dealmaking momentum and what's cutting through the noise in 2026.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/biopharmas-rebound-keeping-pace-so-far)

---

### ğŸ‡ºğŸ‡¸ Novo gets Chamber of Commerce backing in bid to bring IRA challenge to Supreme Court

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 14:36

> On Wednesday, the U.S. Chamber of Commerce filed an amicus brief calling on the Supreme Court to review a lower court decision that previously rejected Novo Nordisk's challenge of drug pricing provisions in the Inflation Reduction Act. As with other challenges to the IRA, the Chamber argued that the negotiations baked into the law are â€œillusory."

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/novo-gets-chamber-commerce-backing-bid-bring-ira-challenge-supreme-court)

---

### ğŸ‡ºğŸ‡¸ Hims &amp; Hers uses another Super Bowl ad to tackle healthcare affordability

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 13:21

> The minute-long ad, which debuted online Thursday ahead of its broadcast premiere during the Feb. 8 game, starts with a stark claim: â€œRich people live longer,â€ said by the adâ€™s narrator, the rapper and actor Common.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/hims-hers-uses-another-super-bowl-ad-tackle-healthcare-affordability)

---

### ğŸ‡ºğŸ‡¸ Takeda, still in a Vyvanse slog, lifts guidance as it looks to new wave of growth

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 11:26

> The gap between Vyvanse generic sales declines and growth from new products is narrowing, the Japanese company said on its third-quarter 2025 earnings call, which detailed financial performance from the nine months ending on Dec. 31.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/takeda-still-vyvanse-slog-lifts-guidance-it-looks-ahead-new-growth)

---

### ğŸ‡ºğŸ‡¸ As Roche eyes busy 2026, Vabysmo undershoots targets and Tecentriq fails early lung cancer study

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 10:41

> Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of closely watched breast cancer candidate giredestrant draws near. But behind another strong earnings report, a miss from the star eye drug Vabysmo stood out.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study)

---

### ğŸ‡ºğŸ‡¸ Bayer broadcasts patient stories with Tony Romo calling plays in Nubeqa drive

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 10:12

> Bayer has unveiled the next play in its Nubeqa marketing strategy, tapping NFL quarterback-turned-CBS commentator Tony Romo for a campaign in support of its fast-growing prostate cancer drug.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/bayer-broadcasts-patient-stories-tony-romo-calling-plays-nubeqa-drive)

---

### ğŸ‡ºğŸ‡¸ STAT+: A play takes on Novoâ€™s myth and money

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 14:51

> And more biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/biotech-news-golden-calf-novo-nordisk-play-theater/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Sanofi is reprimanded by a U.K. trade group for misleading claims about a Pfizer vaccine

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 13:47

> Sanofi was criticized by a U.K. trade group, which accused it of making misleading claims about its RSV vaccine and disparaging a rival product from Pfizer.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/02/pfizer-sanofi-rsv-vaccine-uk/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimerâ€™s

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 09:30

> Why Bristol Myers Squibb is banking on a decades-old drug to help secure its future.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: As its immunology work draws attention, Sanofi also pushes forward in rare disease

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 06:00

> An experimental Sanofi drug helped improve the neurological problems seen with a rare disease, as the company plans to seek approval.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/sanofi-venglustat-gaucher-rare-disease-neurological-symptoms/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 17:06

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/30/pharma-biotech-jobs-abbvie-merck-biontech-moderna-takeda-novo/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: New rule would force PBMs to disclose drug rebates and other fees

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 15:48

> The proposal would mark a significant change for the secretive PBM industry, which often shields crucial data from its clients.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/30/pbm-drug-rebate-transparency-proposed-rule-department-of-labor/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: AstraZeneca looks to China for obesity drug candidates

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 14:36

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/30/biotech-news-astrazeneca-china-obesity-drug-candidates/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about TrumpRx questions, drugmakers lowering some prices, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 14:35

> Three U.S. senators sent a letter to the HHS Office of Inspector General raising questions about TrumpRx â€” whose structure has yet to be detailed

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/30/trump-telehealth-obesity-pbm-insulin-astrazeneca-china/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: States are the next vaccine battleground

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 17:07

> This is the web edition of STAT's D.C. Diagnosis newsletter.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/state-vaccine-mandates-health-care-ice-minnesota-dc-diagnosis-newsletter/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Oz, other officials meet with key senators to push Trumpâ€™s ideas for lower drug prices

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 16:30

> Trump wants lawmakers to force pharma companies to lower their prices, but it's not clear the GOP is on board.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/mehmet-oz-senate-finance-committee-meeting-most-favored-nations-drug-pricing/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: How Opvee, Indiviorâ€™s powerful overdose antidote, went bust

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 09:30

> Opvee reverses opioid overdose more quickly than Narcan. It also can cause withdrawal symptoms. Harm reduction advocates fought it, and won.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/why-opvee-overdose-antidote-failed-harm-reduction-community-opposition/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Eli Lilly expands work on gene therapies for hearing

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 14:49

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/28/biotech-news-eli-lillly-expands-gene-therapy-for-hearing/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: More high-income countries have used compulsory licenses to gain access to meds, study finds

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 13:00

> More high-income countries have used compulsory licenses to gain access to meds, study finds.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/28/pharma-compulsory-licenses-patents-medicines-wto/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Startup Altido Therapeutics pursues CAR-T for glioblastoma tumors

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 09:30

> Glioblastoma is almost always fatal. Altido Bio is trying to commercialize a CAR-T cell therapy that has shown rare promise.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/28/gene-therapy-nick-leschly-startup-altido-therapeutics-targets-glioblastoma/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: New startup to develop a GLP-1 drug for addiction

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 14:40

> And other biotech news brought to you by The Readout newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/27/biotech-news-glp-1-drug-for-addiction-startup/?utm_campaign=rss)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ FDA Office of Hematology Oncology Products Reorganizes, Renamed Office of Oncologic Diseases

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 15:49
- **é‡è¦æ€§**: â­â­â­â­

> Office Renaming

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/fda-office-hematology-oncology-products-reorganizes-renamed-office-oncologic-diseases)

---

### ğŸ‡ºğŸ‡¸ FDA Rare Disease Innovation Hub

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 22:19
- **é‡è¦æ€§**: â­â­â­

> FDA created the Rare Disease Innovation Hub (the Hub) to serve as a point of collaboration and connectivity between CBER and CDER with the goal of ultimately improving outcomes for patients.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/fda-rare-disease-innovation-hub)

---

### ğŸ‡ºğŸ‡¸ Summary Metrics of Drug Development Tool Qualification Projects Submitted to FDA

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 19:33
- **é‡è¦æ€§**: â­â­â­

> This Table provides the current number of active CDER Drug Development Tool (DDT) Qualification projects overall and by Program (DDT- Animal Model Qualification Program, DDT- Biomarker Qualification Program, DDT- Clinical Outcomes Assessment [COA] Qualification Program). Numbers are also provided by

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/summary-metrics-drug-development-tool-qualification-projects-submitted-fda)

---

### ğŸ‡ºğŸ‡¸ Postmarketing Requirements and Commitments: Reports

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 14:55
- **é‡è¦æ€§**: â­â­â­

> The Food and Drug Administration Modernization Act of 1997 requires FDA to publish annually a notice in the Federal Register containing information on the performance of postmarket studies and clinical trials that FDA requires, or has requested, of manufacturers. Learn more.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/postmarketing-requirements-and-commitments-introduction/postmarketing-requirements-and-commitments-reports)

---

### ğŸ‡ºğŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 21:30
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ğŸ‡ºğŸ‡¸ Prescription Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 19:47
- **é‡è¦æ€§**: â­â­

> The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products. Since the passage of PDUFA, user fees have played an important role in expediting the drug approval process.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 17:32
- **é‡è¦æ€§**: â­â­

> Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots)

---

### ğŸ‡ºğŸ‡¸ Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 15:53
- **é‡è¦æ€§**: â­â­

> Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/food-and-drug-administration-overdose-prevention-framework/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose)

---

### ğŸ‡ºğŸ‡¸ Pain and Arthritis Products Containing Hidden Ingredients

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 21:24

> Learn about the warnings for pain and arthritis products that contain hidden drugs and other hidden ingredients.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/medication-health-fraud-notifications/pain-and-arthritis-products-containing-hidden-ingredients)

---

### ğŸ‡ºğŸ‡¸ Umary contains hidden drug ingredients

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 21:23

> The Food and Drug Administration is advising consumers not to purchase or use Umary, a product promoted and sold for pain on various websites, including https://www.solovital.com and possibly in some retail stores.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/medication-health-fraud-notifications/umary-contains-hidden-drug-ingredients)

---

### ğŸ‡ºğŸ‡¸ Electronic Registration and Listing Compliance Program

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 21:20

> Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL).

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/electronic-registration-and-listing-compliance-program)

---

### ğŸ‡ºğŸ‡¸ Human Drug Compounding

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 21:17

> Compounded drugs can serve an important medical need for certain patients, they also present a risk to patients.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding)

---

### ğŸ‡ºğŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 19:45

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ Eurosirel S.P.A - 690733 - 01/26/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 19:20

> CGMP/Finished Pharmaceuticals/Adulterated

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurosirel-spa-690733-01262026)

---

### ğŸ‡ºğŸ‡¸ Eurosirel S.P.A - 690733 - 11/20/2024

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 19:18

> CGMP/Finished Pharmaceuticals/Adulterated

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurosirel-spa-690733-11202024)

---

### ğŸ‡ºğŸ‡¸ RDEA Pilot Program Disclosure Agreement | Rare Disease Endpoint Advancement Pilot Program

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 17:40

> Disclosure Agreement | Rare Disease Endpoint Advancement Pilot Program

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/rdea-pilot-program-disclosure-agreement-rare-disease-endpoint-advancement-pilot-program)

---

### ğŸ‡ºğŸ‡¸ Novel Drug Approvals for 2025

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 17:33

> Innovative drugs often mean new treatment options for patients and advances in health care for the American public.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots: REDEMPLO

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 17:32

> Drug Trials Snapshots: REDEMPLO

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-redemplo)

---

### ğŸ‡ºğŸ‡¸ CDER Leadership Bios

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 15:36

> CDER Leadership Bios

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cder-leadership-bios)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 15:11

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ En Carta Diagnosticsâ€™ EC Pocket Lyme test receives FDA Breakthrough Device Designation

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-02 14:18
- **é‡è¦æ€§**: â­â­â­â­

> The US sees around 476,000 new Lyme cases every year

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/en-carta-diagnostics-ec-pocket-lyme-test-receives-fda-breakthrough-device-designation/)

---

### ğŸ‡ºğŸ‡¸ Argo Biopharma doses first patient in phase 2b trial of BWâ€‘20829

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-28 14:20
- **é‡è¦æ€§**: â­â­â­

> siRNA therapeutic progresses in global study for patients with elevated Lp(a)

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/argo-biopharma-doses-first-patient-in-phase-2b-trial-of-bw-20829/)

---

### ğŸ‡ºğŸ‡¸ CERo reports encouraging early data from phase 1 trial of CERâ€‘1236

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-29 10:59
- **é‡è¦æ€§**: â­

> CERâ€‘T therapy shows initial safety signals and prompts protocol expansion

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/cero-reports-encouraging-early-data-from-phase-1-trial-of-cer-1236/)

---

### ğŸ‡ºğŸ‡¸ ENA Respiratory begins dosing in phase 2 study of INNAâ€‘051 nasal spray

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-29 10:44
- **é‡è¦æ€§**: â­

> Trial to assess whether onceâ€‘weekly treatment can reduce symptomatic viral respiratory infections

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ena-respiratory-begins-dosing-in-phase-2-study-of-inna-051-nasal-spray/)

---

### ğŸ‡ºğŸ‡¸ BioMed X launches kidney disease project in partnership with the government of Barbados

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-27 13:54
- **é‡è¦æ€§**: â­

> Initiative focuses on population-specific molecular profiling

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/biomed-x-launches-kidney-disease-project-in-partnership-with-the-government-of-barbados/)

---

### ğŸ‡ºğŸ‡¸ ALKâ€™s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-02 14:08

> Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/alks-eurneffy-receives-positive-chmp-opinion-for-emergency-anaphylaxis-treatment-in-children/)

---

### ğŸ‡ºğŸ‡¸ Akari files new patent and advances second ADC targeting CEACAM5

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-28 14:15

> Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/akari-files-new-patent-and-advances-second-adc-targeting-ceacam5/)

---

### ğŸ‡ºğŸ‡¸ Gedeon Richter UK takes over UK rights to cariprazine

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-27 13:47

> Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-02-03 04:14:57*